Table 2. Spectrum of variants.
| P/LP | ||
|---|---|---|
| P/LP | 34 | |
| VUS | 21 | |
| Both P/LP and VUS | 7 | |
| Locus of P/LP variants (N = 41) | ||
| BRCA1 | 27 (66%) | |
| BRCA2 | 7 (17%) | |
| ATM | 3 (7%) | |
| CHEK | 1 (2.4%) | |
| RAD51 | 1 (2.4%) | |
| HMMR | 1 (2.4%) | |
| TP53 | 1 (2.4%) | |
| VUS (21 patients, 25 variants) | ||
| ATM | 2 (9.5%) | |
| BRCA1 | 1 (4.8%) | |
| BRCA2 | 3 (14.3%) | |
| CDH1 | 2 (9.5%) | |
| CHEK2 | 1 (4.8%) | |
| ERCC2 | 1 (4.8%) | |
| FANCA | 1 (4.8%) | |
| FANCE | 1 (4.8%) | |
| FANCI | 1 (4.8%) | |
| MLH1 | 1 (4.8%) | |
| MLH3 | 1 (4.8%) | |
| HMMR | 1 (4.8%) | |
| MRE | 1 (4.8%) | |
| MSH6 | 2 (9.5%) | |
| NBN | 1 (4.8%) | |
| PALB2 | 1 (4.8%) | |
| RAD50 | 3 (14.3%) | |
| RAD51 | 1 (4.8%) | |
| RAD51C | 1 (4.8%) |